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MicroRNA profiles in hippocampal 
granule cells and plasma of rats 
with pilocarpine-induced epilepsy 
– comparison with human epileptic 
samples
Paolo Roncon1, Marie Soukupovà1, Anna Binaschi1, Chiara Falcicchia1, Silvia Zucchini1,2,3, 
Manuela Ferracin3,4, Sarah R. Langley5, Enrico Petretto6, Michael R. Johnson5, 
Gianluca Marucci7, Roberto Michelucci8, Guido Rubboli8,9 & Michele Simonato1,2,3
The identification of biomarkers of the transformation of normal to epileptic tissue would help to 
stratify patients at risk of epilepsy following brain injury, and inform new treatment strategies. 
MicroRNAs (miRNAs) are an attractive option in this direction. In this study, miRNA microarrays were 
performed on laser-microdissected hippocampal granule cell layer (GCL) and on plasma, at different 
time points in the development of pilocarpine-induced epilepsy in the rat: latency, first spontaneous 
seizure and chronic epileptic phase. Sixty-three miRNAs were differentially expressed in the GCL 
when considering all time points. Three main clusters were identified that separated the control and 
chronic phase groups from the latency group and from the first spontaneous seizure group. MiRNAs 
from rats in the chronic phase were compared to those obtained from the laser-microdissected GCL 
of epileptic patients, identifying several miRNAs (miR-21-5p, miR-23a-5p, miR-146a-5p and miR-
181c-5p) that were up-regulated in both human and rat epileptic tissue. Analysis of plasma samples 
revealed different levels between control and pilocarpine-treated animals for 27 miRNAs. Two main 
clusters were identified that segregated controls from all other groups. Those miRNAs that are 
altered in plasma before the first spontaneous seizure, like miR-9a-3p, may be proposed as putative 
biomarkers of epileptogenesis.
Temporal lobe epilepsy (TLE) is the most common form of epilepsy in adults. It often develops second-
ary to an initial brain insult (e.g. trauma, tumor or stroke), after a latency period in which patients are 
apparently well. Thus, at-risk patients can often be identified, but it is currently impossible to predict 
who will actually develop epilepsy and who will not. Moreover, available antiepileptic drugs are symp-
tomatic agents that are not useful in preventing the development of the disease and are ineffective in 
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approximately one-third of patients with epilepsy1. Thus, there is an urgent need not only to develop new 
therapies for drug-resistant epilepsy, but also to identify antiepileptogenic therapies that can prevent the 
disease in at-risk individuals1–3. To do so, it is essential to better understand the mechanisms of epilep-
togenesis and drug-resistance. Moreover, the development of biomarkers for epileptogenesis following 
brain injury would facilitate clinical trials of novel antiepileptogenic therapies by allowing those patients 
at the greatest risk of epilepsy to be identified1,4,5. MicroRNAs (miRNAs) provide an opportunity as both 
therapeutic targets and biomarkers of epileptogenesis.
MiRNAs are small (~22 nt) non-coding RNAs that regulate the expression of target mRNAs at the 
post-transcriptional level6. Experimental evidence has demonstrated that miRNAs are involved in heter-
ogeneous brain functions7,8 including neuroinflammation9, synaptic remodeling10, and neuronal death11. 
Thus, it can be hypothesized that specific miRNAs may regulate genetic programs leading to hyperex-
citability in the brain and, as such, represent new therapeutic targets. Moreover, miRNAs are found in 
the blood, where their levels are affected by disease states12–15 and are therefore attractive candidates as 
biomarkers for stratifying patients at highest risk of epilepsy following brain injury16,17.
Recently, alterations in miRNA expression levels have been described both in the brain of epilepsy 
patients and in animal models of epilepsy. In humans, Kan and colleagues performed a genome-wide 
profiling of TLE, identifying a miRNA signature of hippocampal sclerosis18. Likewise, a recent study 
demonstrated the implication of miR-487a in granule cell pathology19. In animal models, changes in 
miRNA expression levels in the hippocampus have been reported in multiple studies in the latency 
period after an epileptogenic insult and in the chronic epileptic state20–24. Unfortunately, all these studies 
have multiple limitations. First, the brain tissue was the whole hippocampus or a mechanically-dissected 
hippocampal sub-region in most studies, which implicates not only great heterogeneity in terms of cell 
composition, but also a different representation of different cell types in controls and epileptic samples, 
as the epileptic hippocampus is characterized by cell loss and astrocytosis. Only Zucchini et al.19 micro-
dissected a specific cell population (the granule cells), but the comparison was between epileptic samples 
with or without granule cell pathology, i.e. no healthy controls. Second, human studies lacked a proper 
control, in that the epileptic tissue was from surgeries and the control from autopsies. Third, no detailed 
evaluation of the changes in the course of disease was performed. Forth, blood samples were not col-
lected and analyzed, except for Gorter et al.24
The aim of this study was to fill the gaps left by the previous ones of this kind. Specifically, we 
performed a systematic evaluation of the miRNAome in a specific cell population of the hippocampus 
(the laser microdissected granule cell) and in plasma samples, at multiple time-points in the course of 
pilocarpine-induced epilepsy in rats: early and late latency, at the time of the first spontaneous seizure 
and in the chronic period. Further, we compared results from rats in the chronic phase of epilepsy with 
post-mortem human epileptic and control granule cell samples.
Results
Granule cells. miRNA clustering. We first evaluated miRNA expression in the laser-microdissected 
granule cell layer (GCL) of rats sacrificed at multiple time-point following pilocarpine-induced SE: 4 and 
7 days after SE, 12 h after the first spontaneous seizure and 50 days after the first spontaneous seizure. 
To detect changes in miRNA expression levels regardless of the time point, we first analyzed differential 
miRNA expression levels in the GCL between control and epileptic rats. We detected significant changes 
in the expression of 63 miRNAs (Supplementary Table S1). Hierarchical clustering of all samples per-
formed with these 63 miRNAs revealed three main clusters that separated the control and chronic phase 
groups from rats sacrificed during latency (4 and 8 days after SE) and from those sacrificed after the first 
spontaneous seizure (Fig. 1). However, control and chronic formed distinguishable sub-clusters.
Changes in expression were also separately analyzed for each time point. As compared with controls, 
we detected significant changes in 33 miRNAs during latency (4 and 8 days after SE), 33 miRNAs at 
the time of the first spontaneous seizure, and 25 miRNAs in the chronic period (Supplementary Tables 
S2–S4).
miRNA expression pattern. Variations in miRNAs levels in the GCL at different time points were then 
analyzed in detail. Group to group comparison revealed 6 different miRNA expression patterns in the 
GCL. First, a subgroup of miRNAs (miR-15b-5p, miR-17-5p, miR-18a-5p, miR-19a-3p, miR19b-3p, miR-
20a-5p, miR-20b-5p, miR-21-5p, miR-23b-5p, miR-24-3p, miR-27a-3p, miR-92a-3p, miR-93-5p, miR-
142-3p, miR-344b-2-3p, miR-431, miR-466b-5p and miR-674-3p) displayed increased expression levels 
during latency (4 and 8 days after SE), decreased their expression levels at the time of the first spontane-
ous seizure and returned to control levels in the chronic phase (Fig. 2, Supplementary Fig. S1). All these 
miRNAs displayed a peak in expression levels 8 days after SE, except for miR-21-5p, miR-27a-3p, miR-
142-3p and miR-674-3p that peaked earlier (4 days after SE). Another subgroup of miRNAs displayed an 
opposite pattern, i.e. decreased expression during latency: miR-7a-1-3p, miR-107-3p, miR-138-5p, miR-
139-3p, miR-186-5p, miR-204-5p, miR-222-3p, miR-324-3p and miR-505-3p were significantly decreased 
during latency (peak at 4 days after SE), then gradually returned to control levels (Fig. 2, Supplementary 
Fig. S2).
www.nature.com/scientificreports/
3Scientific RepoRts | 5:14143 | DOi: 10.1038/srep14143
Some miRNAs (miR-129-1-3p; miR-129-2-3p, miR-129-5p, miR181c-5p, miR181d-5p, miR-409a-5p, 
miR-655 and miR-874-3p) were up-regulated (Fig.  2, Supplementary Fig. S3A), whereas others (miR-
296-5p, miR-500-3p and miR-652-3p) were down-regulated only in the chronic phase, while not being 
significantly altered during latency (Fig.  2, Supplementary Fig. S3B). Finally, other subsets of miRNAs 
were either up-regulated (miR-23a-3p, miR132-3p, miR-146a-5p, miR-154-3p, miR-181d-5p, miR-212-3p, 
miR-212-5p, miR-344b-5p, miR-380-3p, miR-410-3p, miR-433-3p and miR-3584; Fig. 2, Supplementary 
Fig. S4), or down-regulated (miR-29c-5p, miR-30a-5p, miR-30c-2-3p, miR-30e-3p, miR-138-5p, miR-
140-3p, miR-551b-3p and miR-652-3p; Fig. 2, Supplementary Fig. S5) during all phases of the disease.
Network analysis. We then performed a network analysis of miRNAs whose expression was signifi-
cantly altered during latency, because pathways identified in this manner may play a role in epileptogen-
esis. Targets for each miRNA were obtained using the mirDB and TargetScan algorithms and filtered to 
include those which were expressed in the rat dentate gyrus. Seven significant clusters of miRNAs were 
identified at 10% false discovery rate (FDR) level (Fig. 3A). GO/KEGG enrichment highlighted five of 
them as having a potential role in epileptogenesis.
Figure 1. Cluster analysis of miRNAs differentially expressed in the granule cell layer (GCL) at different 
time points in the course of pilocarpine-induced epilepsy. Heat map representation of the average 
expression of the 63 differentially expressed miRNAs in the GCL of epileptic and control animals. Each 
column represents an individual animal and each row represents one miRNA, as indicated. Colors represent 
the expression level fold change: higher-red, lower-green. Analysis was performed on differentially expressed 
miRNAs (FDR > 10%), using the Person correlation; for cluster image preparation an additional step of 
normalization on gene median across all samples was added.
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Cluster 1, composed by miR-674-3p, miR-505-3p and miR-212-5p, was up-regulated during epilep-
togenesis (4 and 8 days after SE). Target analysis identified eight significant pathways: purine metabo-
lism (adjusted P = 0.016); metabolic pathways (adjusted P = 0.013); axon guidance (adjusted P = 0.013); 
pyrimidine metabolism (adjusted P = 0.0091); peroxisome proliferator-activated receptors (PPAR) sign-
aling pathway (adjusted P = 0.0074); adipocytokine signaling pathway (adjusted P = 0.0074); glycolysis 
and gluconeogenesis (adjusted P = 0.0074); SNAp REceptor (SNARE) interactions in vesicular transport 
(adjusted P = 0.0064; Fig. 3B). “Axon guidance” and “SNARE interactions in vesicular transport” were 
the categories most likely to play a role in latency. Two target genes per pathway were highlighted: the 
synaptosomal-associated protein 29 kDa (Snap 29) and the vesicle-associated membrane protein 3 (Vamp 
3) in the axon guidance pathway; the ephrin B1 (Efnb1) and the chemokine ligand 12 (Cxcl12) in the 
SNARE interactions in vesicular transport pathway (Supplementary Fig. S6A).
Cluster 3 was composed by two up-regulated microRNAs, miR-142-3p and miR-146a-5p. This cluster 
was associated with four different pathways including endocytosis (adjusted P = 0.013), cytokine-cytokine 
receptor interaction (adjusted P = 0.013), PPAR signaling pathway (adjusted P = 0.003) and general met-
abolic pathway (adjusted P = 0.0008; Fig. 3C). Two target genes in cytokine-cytokine receptor interaction 
Figure 2. Time course patterns of miRNA expression in the rat granule cell layer (GCL). The boxplots 
depict the time course of expression for 6 of the miRNAs identified as significant with a false discovery rate 
(FDR) < 10% in the GCL by using one-way ANOVA. Each boxplot represents 4 animals. These miRNAs 
were chosen as representative of the different patterns that were observed: up-regulation (miR-21-5p) or 
down-regulation (miR-222-3p) during latency; up-regulation (miR-181c-5p) or down-regulation (miR-
500-3p) in the chronic period; up-regulation (miR-146a-5p) or down-regulation (miR-551b-3p) in the 
entire course of the disease. The time courses of the other significantly modified miRNAs are shown in 
Supplementary Figs. S2, S3, S4, S5 and S6. *p < 0.05; **p < 0.01; ***p < 0.001; Tukey’s test.
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pathway were highlighted; the transforming growth factor β receptor 1 (Tgfbr1) and the growth hor-
mone receptor (Ghr; Supplementary Fig. S6B).
Cluster 4 included miR-181c-5p and miR-181d-5p. The KEGG analysis identified multiple pathways 
associated with the target genes of these two miRNAs. In particular, the neurotrophin signaling pathway 
(adjusted P = 0.016), with tumor necrosis factor receptor superfamily, member 11b (Tnfrsf11b), protein 
kinase C, delta (Prkcd) and calmodulin 1 (Calm1); and the cytokine-cytokine receptor interaction path-
way (adjusted P = 0.009), with the platelet-derived growth factor receptor, alpha polypeptide (Pdgfra) 
and the chemokine ligand 10 (Cxcl10; Fig. 3D and Supplementary Fig. S6C).
MiR-344b-5p and miR-20b-5p were in cluster 5. They were associated with different cancer related 
pathways, endocytosis (adjusted P = 0.044), MAPK signaling (adjusted P = 0.0081) and neuroac-
tive ligand-receptor interaction (adjusted P = 0.0015; Fig.  3E). Target genes involved in neuroactive 
ligand-receptor interaction category were the glycine receptor alpha 2 (Glra2), the gamma-aminobutyric 
acid B receptor 2 (Gabbra2), the galanin receptor 1 (GalR1) and the glutamate receptor ionotropic AMPA 
2 (Gria2; Supplementary Fig. S6D).
Interestingly, this combinatorial analysis revealed that some significant clusters of miRNAs might 
correlate with identical pathways.
Figure 3. Network analysis. Predicted gene targets for each miRNA dys-regulated during latency (4 and 
8 days after SE), obtained using the mirDB and TargetScan algorithms, were filtered with all miRNAs 
expressed in the dentate gyrus of rats (database GSE49850). (A) Clusters of miRNAs identified at 10% false 
discovery rate (FDR) level. (B) Cluster 1. (C) Cluster 3; (D) Cluster 4. (E) Cluster 5. Gene ontology (GO) 
and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were performed using webgestalt, p < 0.05.
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RT-qPCR. A large subset of miRNAs whose expression was significantly modulated in the GCL in 
our model and that was identified in significant clusters through network analysis was validated using 
RT-qPCR in a different cohort of cases. Overall, the data were highly consistent with those obtained using 
microarray. In fact, the expression patterns of miR-20b-5p, miR-142-3p, miR-181d-5p, miR-212-5p, miR-
344b-5p and miR-674-3p were identical to those observed using the microarray, and those of miR-21-5p 
and miR-146a-5p were very similar, although not identical (Fig. 4). Even if displaying the same patterns 
observed with the microarray, the expression levels of mir-181c-5p, miR-433-3p, miR-505-3p and miR-
551b-3p were not significantly different from controls (Fig. 4).
Human tissue. Next, we asked what the relevance of these findings could be for human epilepsy. 
In humans, comparison can only be made between chronically epileptic and non-epileptic controls. 
However, a technical hurdle exists with human studies, because the only available human controls are 
from autopsies, whereas the epileptic tissue is generally from surgical resections. Thus, we first wanted to 
ensure that the comparison of autoptic and bioptic material was valid. We performed miRNA microar-
ray on laser-microdissected GCLs from 10 epileptic patients who underwent surgery, two autopsies 
of epileptic patients and 10 aged-matched autopsy controls (epileptic: age 70 and 46, both females; 
non-epileptic: age 47 ± 7, range 34–57, 3 males, 7 females; all 12 dead by acute pulmonary or cardiac 
disease). Unfortunately, the two autoptic epileptic did not segregate with the other epileptic as expected, 
but with the control autoptic. This indicates that the tissue origin (i.e. bioptic or autoptic) had greater 
Figure 4. Relative expression of selected miRNAs in the granule cell layer, as detected using qPCR. Five 
rats per group. *p < 0.05; **p < 0.01; Tukey’s test.
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importance than the disease background (data not shown, manuscript in preparation). Therefore, here 
we restricted the comparison between the 2 epileptic and the 10 non-epileptic autoptic samples.
We compared the miRNA species modulated in chronic epileptic rats and in human cases. We iden-
tified four miRNAs (miR-21-5p, miR-23a-5p, miR-146a-5p and miR-181c-5p) that were up-regulated in 
both epileptic humans and rats (Table 1). Moreover, the comparison displayed similar changes in expres-
sion levels between epileptic (human cases and rats) and controls, except for miR-146a-5p, that increased 
more in rats than in humans (fold change equals 21.24 in rats and 3.63 in humans).
Plasma. Finally, to investigate the possibility of using miRNAs in peripheral blood as potential bio-
markers of epileptogenesis, we analyzed plasma samples collected from the experimental and control rats 
for the study of the hippocampal GCL.
This analysis revealed different levels between control and pilocarpine-treated animals in one miRNAs: 
only miR-91-3p showed significant differential expression at a 10% FDR level (adjusted P = 0.08). This 
may be due to the larger variability found in circulating miRNAs levels as compared to other tissues25. 
Therefore, to gain an exploratory view of the miRNA expression patterns in plasma, we relaxed the sig-
nificance threshold to an unadjusted P < 0.05, which resulted in 27 miRNAs of interest (Supplementary 
Table S5). Hierarchical clustering also generated two main clusters that separated controls from all other 
groups, with the exception of two animals in early latency group (4 days after SE) and one in the chronic 
phase group, which segregated with the controls (Fig. 5A). Within the cluster including all pilocarpine 
animals, rats belonging to the single experimental groups displayed a clear tendency to form distinct 
sub-clusters.
Within these 27 miRNAs, we detected 4 different expression patterns in the plasma of rats sacrificed 
at different time points of the disease history. MiR-9a-3p displayed highly increased levels at the earlier 
stage of latency (4 days after SE), then normalized to control levels at the following time points (Fig. 5B; 
Supplementary Fig. S7A). A second pattern was about the opposite: miR-466b-1-3p, miR-494-3p and 
miR-598-5p displayed significantly decreased plasma levels during latency, and a tendency to return to 
the control levels in the chronic stage (Supplementary Fig. S7B). Another couple of miRNAs (miR-32-3p 
and miR-300-3p) was down-regulated around the time of the first spontaneous seizure (Supplementary 
Fig. S7C). Finally, miR-30c-2-3p, miR-101b-3p, miR-142-3p, miR-142-5p, miR-181a-1-3p, miR-374-5p, 
miR-466c-3p, miR-1188-3p, miR-3065-3p and miR-3582 were significantly down-regulated in the chronic 
stage (Supplementary Fig. S7D).
The only miRNA dysregulated both in the GCL and in plasma was miR-142-3p. The patterns of dys-
regulation, however, were totally different: miR-142-3p was up-regulated in the GCL during latency and 
down-regulated in plasma in the chronic period. MiR-9a-3p and miR-142-3p were chosen for RT-qPCR 
validation in the same cohort of samples, displaying the same patterns observed in the microarray, even 
if they did not reach statistical significance.
Discussion
The main findings of the present study are the following. First, the overall analysis of the rat GCL revealed 
three main clusters of miRNAs that separated the control and chronic phase groups from rats sacrificed 
during latency (4 and 8 days after SE) and from those sacrificed after the first spontaneous seizure. This 
identifies a distinct miRNA expression pattern associated with the latency period between brain injury 
and first spontaneous seizure that may reveal epileptogenic pathways. Second, the chronic phase was 
accompanied by significant alterations in miRNA expression in the rat GCL, and comparison with data 
from epileptic patients identified several miRNAs (notably miR-21-5p, miR-23a-5p, miR-146a-5p and 
miR-181c-5p) that were up-regulated in both human and rat epileptic hippocampus. MiRNAs whose 
expression is altered in the GCL may be implicated in the mechanisms of epileptogenesis and/or in the 
generation of seizures, and may therefore represent new therapeutic targets. Third, analysis of plasma 
samples revealed that, while at relaxed threshold, 27 miRNAs were able to discriminate the controls 
from all other groups. Those miRNAs that are altered in plasma before the first spontaneous seizure, like 
miR-9a-3p, may be worth further investigation into their use as potential biomarkers of epileptogenesis.
The miRNA expression analysis revealed interesting overlaps between our work here and the two pre-
viously published studies focusing on the dentate gyrus (DG)23,24, both in terms of miRNAs modulated 
Chronic rats Patients
Fold 
change Regulation
Fold 
change Regulation
miR-21-5p 1.24 Up 1.93 Up
miR-23a- 5p 1.83 Up 3.35 Up
miR-146a-5p 21.24 Up 3.63 Up
miR-181c-5p 1.91 Up 1.88 Up
Table 1.  miRNAs expression patterns in chronically epileptic rats and patients.
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Figure 5. Plasma miRNA levels. (A) Heat map representation of the average levels of the 27 differentially 
expressed miRNAs in the plasma of epileptic and control animals. Each column represents an individual 
animal and each row represents one miRNA, as indicated. Colors represent the expression level fold change: 
higher-red, lower-green. Analysis was performed on differentially represented miRNAs using the Person 
correlation. (B) The boxplots depict the time course for 4 of the miRNAs identified as significant by using 
one-way ANOVA. Each boxplot represents 5 animals. These miRNAs were chosen as representative of the 
different patterns that were observed: up-regulation (miR-9a-5p) or down-regulation (miR-598-5p) during 
latency, down-regulation in the late latency - first spontaneous seizure period (miR-381-3p) and down 
regulation in the chronic stage (miR-142-5p). (C) Relative levels of miR-9a-5p and miR-142-3p, as detected 
using qPCR. Five rats per group. *p < 0.05; **p < 0.01; ***p < 0.001; Tukey’s test.
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in the latency and in the chronic phase, even if: 1) different epilepsy models were employed in these 
other studies, namely amygdala and perforant path stimulation-induced SE; 2) the DG was mechanically 
dissected from other hippocampal regions in these other studies, and therefore the results are the com-
bination of the varying alterations in miRNA levels occurring in multiple cell populations (in contrast 
with our laser-dissection approach, that ensures a nearly pure granule cell preparation). Other studies20–22 
used the whole hippocampus, emphasizing the latter limitation, and therefore will not be used for com-
parison in the frame of the present discussion.
Commonalities with other studies are particularly interesting, because they may represent 
disease-specific, rather than model-specific alterations. Since the pathophysiological implications would 
be very different, we will here discuss separately findings related to latency (early and late latency in the 
present study) and findings related to the chronic state that follows diagnosis in humans (first seizure 
and chronic murine groups plus the human cases in this study). Finally, we will discuss the data obtained 
from peripheral blood.
Latency. Our study and other relevant data sets23,24 identified the up regulation of three miRNAs 
(miR-21-5p, miR-212-3p and miR-132-3p) during latency. Furthermore, we and Gorter et al.24 observed 
the up-regulation of miR-17-5p, miR-20a-5p, miR-23a-3p and the down-regulation of miR-139-5p, 
whereas we and Bot et al.23 observed the down-regulation of miR-551b-3p.
Alterations on these miRNA levels suggest a role in the mechanism of epileptogenesis, a concept that 
is supported by analysis of their potential targets. For example, the up-regulation of miR-21-5p may be 
involved in the initiation of the cell signaling pathway associated with epilepsy26. Moreover, mutations 
in the myocyte enhancer factor 2C (MEF2C) gene, a neuronal transcription factor that may have a role 
in neuronal dysfunction and neurodegeneration27, has been observed in patients with epilepsy28 and has 
been identified as a target of miR-21-5p and miR-21-3p27. Sestrin 1 (SESN1), a predicted target of miR-
21-5p, is down-regulated during latency after amygdala stimulation23. This finding, combined with the 
evidence that another member of the sestrins family, SESN3, controls a proconvulsant transcriptional 
program in human TLE29, suggests a correlation between miR-21-5p and the mechanisms that lead to 
seizures onset.
Further evidence for a direct involvement of the identified miRNAs in the mechanisms of epilepto-
genesis derived from network analysis. Our network analysis, based on miRNAs dysregulated during 
latency in the GCL, highlighted the presence of 4 clusters of miRNAs. Cluster 3 (that includes miR-
142-3p and miR-146a-5p) and cluster 4 (including miR-181c-5p and miR-181c-5p) are connected to the 
“cytokine-cytokine receptor interaction” signaling pathway, which suggests a neuroinflammatory role 
for those miRNAs. In keeping with this idea, evidence in the literature supports that miR-146a-5p regu-
lates the astrocyte-mediated inflammatory response by influencing IL-1β , IL-6 and COX-2 signaling24,30. 
Cluster 4, together with cluster 1 (that includes miR-674-3p, miR-505-3p and miR-212-5p) and cluster 
5 (including miR-144b-5p and miR-20b-5p), may also strongly influence neuronal activity. In fact, their 
predicted targets in the rat DG are involved in axon guidance and SNARE interaction (cluster 1), neuro-
trophin signaling (cluster 4) and neuroactive ligand receptor (cluster 5). Axon guidance has been linked 
to epilepsy, the sprouting of mossy fibers (the axons of granule cells) being the best characterized of 
axonal reorganization in TLE. Although epilepsy-associated mossy fiber sprouting has been extensively 
studied31–33, its underlying molecular mechanisms are still poorly understood, and the present findings 
suggest a role for this cluster of miRNAs. Interestingly, the predicted targets of cluster 5 include the 
gamma-aminobutyric acid B receptor 2 (Gabbra2), the galanin receptor 1 (GalR1) and the glutamate 
receptor ionotropic AMPA 2 (Gria2), all genes whose products are implicated in the regulation of excit-
ability and in epilepsy. Specifically, 1) a polymorphism of Gabbra2 is associated with mTLE34; 2) GalR1 
deletion exacerbates hippocampal neuronal loss after kainate administration in mice35, and GalR1 knock-
out mice exhibit spontaneous epilepsy, abnormal EEGs, and altered inhibition in the hippocampus36; 
3) Gria2 in the hippocampus is related to the mechanisms of seizure and neurodegeneration37. Thus, 
this cluster of miRNAs may play a role as a master regulator of multiple mechanisms of epileptogenesis. 
Functional studies aimed at establishing the functional role of these miRNAs in TLE will represent the 
obvious continuation of this study.
Most of the miRNAs up-regulated during latency in the GCL displayed pick expression levels in 
the late phase of latency (7 days after SE), but a subset (miR-21-5p, miR-674-3p and miR-3564-5p) 
was increased the most 4 days after SE. It can be hypothesized that these changes correspond to differ-
ent “waves” of the epileptogenesis process, which may represent different windows of opportunity for 
therapy38.
Chronic period. Regarding the chronic group, both the present dataset and the other two that we 
considered relevant to this Discussion23,24 identified the up-regulation of miR-21-5p, miR-23a-5p and 
miR-146a-5p. Up-repulation of these miRNAs has been reported also in other studies21,39,40. Moreover, 
we and Gorter et al.24 observed the up-regulation of miR-212-5p, whereas we and Bot et al.23 observed 
the up-regulation of miR-433-3p.
MiR-23a-5p has been proven to be a regulator of cell growth and apoptosis41. Furthermore, it has 
been identified as a negative regulator of lamin B1, thereby contributing to the process of oligodendroglia 
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development and myelin formation42. MiR-146a-5p is strictly associated with the astrocyte-associated 
immune response both in epileptic patients and in vivo models24,39.
As described, we identified different expression patterns of miRNAs that were up or down-regulated 
at the time of the first seizure and during the chronic period, showing slight but significant differences 
between the two phases. Continuing modifications in the expression pattern of miRNAs in the course 
of chronic epilepsy support the hypothesis that epileptogenesis is a dynamic process that continues even 
after the initial diagnosis of the disease, i.e. after the initial spontaneous seizures1.
The comparison between chronic epileptic rats and the human cases identified four miRNAs (miR-
21-5p, miR-23a-5p, miR-146a-5p and miR-181c-5p) that are similarly up-regulated in expression levels 
in both species. Interestingly, miR-23a-5p and miR-146a-5p are in common with the other two rat data 
sets that were taken as primary comparator in this Discussion23,24. As for miR-181c-5p, it was highlighted 
by network analysis in cluster 4, and implicated in cytokine-cytokine receptor interaction and in the 
inflammatory response. Thus, even if preliminary being based on a small number of patients, human data 
appear to confirm those obtained in animal models, suggesting that animal data may be representative of 
the human situation also under conditions (latency) that cannot be directly explored in humans.
Blood. There is great need of diagnosis tools to identify those individuals, among those at risk, that 
will actually develop epilepsy or to stratify epileptic patients with different prognosis. Changes in extra-
cellular miRNA levels have been observed in association with neurological diseases in various body fluids 
including plasma, putting forward the concept that miRNAs may represent noninvasive or minimally 
invasive, clinically useful biomarkers16,17,24, even if the biological function of plasmatic miRNAs is still 
obscure (it has been hypothesized that they represent a form of cellular communication whereby cells can 
interact at distance by transfer of exosomes or microvesicles containing miRNAs through the systemic 
circulation43,44).
Two previous studies performed microarrays on blood samples. One described changes in circulating 
miRNA levels 24 h after ischemic stroke, intracerebral hemorrhage and kainate seizures45. The other24 
performed the analysis in plasma samples obtained from the trunk blood, reporting an increase in miR-
142-5p levels during the acute phase, miR-21-5p in the early stage and of miR-146a-5p in the chronic 
stage, that reflect parallel changes in miRNAs expression observed in the brain. Unfortunately, the com-
plete dataset has not been made available by this study, and it is therefore unclear if all plasma miRNAs 
or only those 3 change in the same manner in plasma and in the brain.
Here, we studied the expression levels of circulating miRNAs in plasma separated by blood collected 
from animals through an intracardiac withdrawal, a technique that avoids contamination with others cell 
populations. Analysis of plasma samples revealed different levels between control and pilocarpine-treated 
animals for 27 miRNAs that segregated controls from all other groups. We identified a single miRNA, 
miR-142-3p that was altered both in plasma and in the brain, but the pattern of expression was different 
in that it was down-regulated in the former and up-regulated in the latter. Based on our data, therefore, 
it seems unlikely that changes in circulating miRNAs levels are correlated to the changes in miRNAs 
expression in the brain.
Although it is impossible, at the current stage of knowledge, to speculate on the biological significance 
of changes in plasma, it can nonetheless be proposed that those miRNAs that are altered in plasma before 
the first spontaneous seizure, like miR-9a-3p, are putative biomarkers of epileptogenesis. Further studies 
are needed to gain insight into the origin and the biological significance of circulating miRNAs, and to 
understand their functional role in TLE and other neurological disorders. The present data, however, 
are relevant to the identification of biomarkers that can predict the development of epilepsy in at-risk 
subjects.
In conclusion, the present results identify a distinct miRNA expression pattern associated with latency 
in the rat pilocarpine model and reveal putative epileptogenic pathways, suggesting that miRNAs rep-
resent attractive therapeutic targets for the prevention of epilepsy. Moreover, we found overlap human 
and rat databases in the chronic stage, supporting the notion that animal data are representative of the 
human situation. There are many commonalities between our data and other publicly available datasets 
obtained from in vivo models of TLE. Those miRNAs whose expression changes are in common through 
different datasets are particularly attractive candidates for further investigation, being disease-, rather 
than model-specific. Finally, results obtained from rat plasma samples suggest that circulating miRNAs 
may be used as biomarkers of epilepsy. The major hits identified in this study, like miR-9a-3p, should be 
now challenged in other epilepsy models in which only a subset of animals develop spontaneous seizures, 
in order to verify that they can actually stratify subjects that will or will not develop the disease.
Methods
Animals. Male Sprague-Dawley rats (250–350 g; Harlan, Italy) were used for pilocarpine experiments. 
They were housed under standard conditions: constant temperature (22–24 °C) and humidity (55–65%), 
12 h light/dark cycle, free access to food and water. Procedures involving animals and their care were 
carried out in accordance with European Community, national and local approved guidelines, laws and 
policies. All experimental protocols were approved by the University of Ferrara Ethical Committee for 
Animal Experimentation and by the Italian Ministry of Health. All animals were (i) acclimatized to 
laboratory conditions for at least 1 h before the start of the experiment, (ii) used only once during the 
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pilocarpine protocol and (iii) euthanized at different times points by anesthetic overdose. The num-
ber of animals was kept as small as possible and the ARRIVE (Animal Research: Reporting In Vivo 
Experiments46) have been followed.
Surgery. Surgery was carried out to implant the electrodes for EEG recordings. Rats were secured to a 
stereotaxic apparatus, with the nose bar positioned at + 5 mm, under ketamine/xylazine (43 and 7 mg/Kg 
i.p.) anesthesia. Anesthesia was then maintained using isoflurane (1.4% in air; 1.2 ml/min). A recording 
electrode was implanted into the right ventral hippocampus (A: − 3.4 mm; L: + 4.5 mm; P: + 6.5 mm 
to bregma47). A reference electrode was placed on the skull. Rats were allowed 7 days to recover from 
surgery.
Pilocarpine. Rats were randomly assigned to groups that received a single injection of 
methyl-scopolamine (1 mg/kg, s.c.) 30 min prior to pilocarpine (370 mg/kg, i.p.) or a single injection of 
methyl-scopolamine 30 min prior to vehicle (0.9% NaCl solution; control animals), and their behavior 
was observed by experienced researchers for at least 6 h thereafter. Within the first 20–25 min after pilo-
carpine injection, 83% of the animals developed seizures evolving into recurrent generalized convulsions 
(status epilepticus, SE). SE was interrupted 3 h after onset by administration of diazepam (20 mg/kg, 
i.p.). For 1–2 days following SE interruption, animals occasionally exhibited short-lasting seizures and 
lost weight (15–20%). Thereafter, they recovered and entered a period of apparent wellbeing (latency). 
However, one fourth of the animals that entered SE (i.e. 21% of those administered pilocarpine) died 
during SE or within 1–2 days.
Test and interspersed control animals were then randomly assigned to four experimental groups rep-
resenting different phases of the natural history of the disease: early latency (4 days after SE), late latency 
(8 days after SE), first spontaneous seizure (11 ± 1 days after SE), chronic (50 days after the first spon-
taneous seizure). Inclusion criteria were (i) development of convulsive SE within 1 h after pilocarpine 
administration and (ii) weight gain within the first week after SE.
Video and electroencephalography recordings. Video and video-EEG recordings were used to 
verify the hippocampal seizure onset and the disease progression in chronic animals. Convulsive sei-
zures were assessed by 24/24-h video monitoring, performed using a digital video surveillance system 
DSS1000 (V4.7.0041FD, AverMedia Technologies, USA). Video monitoring was started approximately 
6 h after pilocarpine administration (i.e. at the end of direct observation by the researchers – see above) 
and continued until day 5 when EEG recording was applied for proper identification of the first spon-
taneous seizure. Continuous video-EEG monitoring was started from day 5 after SE until the day of the 
first spontaneous seizure. Video-EEG monitoring (hardware system MP150 and software AcqKnowledge 
4.3, all from Biopac, USA) was started at day 5 because, as previously reported48,49, we do not observe 
spontaneous seizures earlier than 8–9 days after pilocarpine administration under the experimental con-
ditions employed in this study. EEG seizures were categorized and measured as periods of paroxysmal 
activity of high frequency (> 5 Hz) characterized by a > 3-fold amplitude increment over baseline with 
progression of the spike frequency that lasted for a minimum of 3 s33,50. Seizure severity was scored using 
the scale of Racine51: 1, chewing or mouth and facial movements; 2, head nodding; 3, forelimb clonus; 
4, generalized seizure with rearing; 5, generalized seizure with rearing and falling. In the chronic phase, 
animals were continuously video-EEG recorded for a week after the first spontaneous seizure, for a week 
before the sacrifice and 48 h per week between the first spontaneous seizure and the killing.
Tissue preparation. Rats were killed by decapitation under an anesthetic overdose. Before being 
killed, rats were anesthetized with ketamine (870 mg/kg) and xylazine (13 mg/Kg), and a blood sam-
ple was collected through intracardiac withdrawal. Blood samples were added EDTA (ethylenediamine-
tetraacetic acid disodium salt dehydrate, Sigma, Germany) to prevent clotting and plasma was separated 
by centrifugation at 1000 rcf for 2 minutes and the supernatant was centrifuged at 2500 rcf for 2 min-
utes. This procedure ensured low platelet contamination52. Samples were separated in 200 μ l aliquots 
and stored at − 80 °C.
Brains were rapidly removed, frozen in isopentane and stored at –80 °C until use. Coronal sections 
(20 μ m thick) were cut across the entire hippocampus, plates 40–52 of Pellegrino et al.47 and mounted 
onto slides for laser microdissection (MembraneSlides PEN-Membrane 2,0 μ m, Leica). Sections were 
fixed according to a slight modification of a published protocol53: ethanol 70% in diethyl pyrocarbonate 
(DEPC) water for 5 min, rinse in distilled DEPC water, incubation in Mayer’s hematoxylin solution 0.1% 
(Sigma) for 5 min, another wash in DEPC water; finally, section were dried at room temperature for 
10 min before being stored at –80 °C. This procedure ensured the best yield and quality of extracted 
RNA, as compared to other published procedures, in side-by-side testing experiments conducted in the 
lab before initiating the processing of the tissue employed in the present study.
Human Samples. All human hippocampal tissue was from autopsies of 2 epileptic and 10 non-epileptic 
patients who died of acute lung or heart pathologies. All autoptic material was from the tissue archives 
of the Bellaria Hospital (Bologna, Italy). The study was approved by the Ethics Committee of Bologna 
(Comitato Etico Indipendente dell’Azienda USL della Città di Bologna). Since this was a pilot study in 
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a small cohort of cases, all from archive samples of patients who died years ago, the Ethical Committee 
acknowledged the impossibility to collect informed consents and approved the study under the condition 
to strictly ensure anonymity. All the methods were carried out in accordance with the approved guide-
lines, and all information regarding the human material was managed using anonymous numerical codes 
and samples were handled in compliance with the Helsinki declaration (http://www.wma.net/en/30pub-
lications/10policies/b3/). Specimens were formalin-fixed and paraffin-embedded. They were de-waxed 
using Bio-Clear (Bio-Optica, Milan, Italy), washed in ethanol and stained with hematoxylin and eosin, 
as indicated in Zucchini et al.19.
Laser microdissection, RNA purification and profiling. Ten-micron-thick sections were cut using 
a microtome and collected in slides for laser microdissection (LMD). LMD was performed essentially as 
previously described19,54,55. Briefly, PEN-membrane slides were mounted on a Leica LMD6000B system 
(Leica Microsystem, Wetzlar, Germany) with the sections facing downwards. The intensity, aperture and 
cutting velocity were calibrated to obtain the sharpest cut with the minimal intensity, then the pulsed UV 
laser beam was carefully directed along the borders of the dentate gyrus GCL (Fig. 6). The microdissected 
region was then transferred by gravity into a 0,2 ml Eppendorf tube cap placed directly underneath the 
tissue section. Tissue collection was verified by inspecting the tube cap. Granule cells were collected from 
at least 9 slices per animal and 3–4 slices per patient, in order to obtain an adequate amount of tissue 
for RNA extraction. Material from all sections from the same animal or patient was pooled together, and 
total RNA purified using an RNA purification kit (miRNeasy Micro kit from QIAGEN Germany, was 
used to purify the RNA in animal samples and RecoverAll™ Total Nucleic Acid Isolation kit from Life 
Technologies, Milan, Italy for human samples). Approximately 250 ng of total RNA were obtained from 
each sample. Every RNA sample was analyzed using an Agilent 2100 Bioanalyzer in order to evaluate 
the quality of total RNA. RNA samples with a RNA Integrity Number (RIN) < 5 (in a 1 to 10 scale) were 
excluded from further analysis.
Total RNA, including microRNAs , was also purified from 200 μ l of plasma samples with a spe-
cific RNA purification kit (miRNeasy Serum/Plasma kit, Qiagen). To ensure effective denaturation of 
proteins, 10 volumes of Qiazol solution were added to one volume of plasma or serum. Samples were 
then thoroughly mixed by vortexing and incubated at room temperature for 5 min56. As internal con-
trol, we employed c. elegans miR-39 miRNA mimic (miRNeasy Serum/Plasma Spike-In Control, Qiagen; 
3.5 μ l, 1.6 × 108 copies/μ l). Total RNA was eluted from column by two sequential elutions with 16 μ l of 
RNase-free water to yield 30 μ l RNA solution. Prior to RNA isolation, all samples were carefully ordered 
to alternate samples from different groups, in order to avoid biases related to batch effects and geographic 
location of samples in the thermocycler block56.
Total RNA was used for microarray analysis (Rat miRNA MicroArray Kit, Human micro-RNA 
Microarray V3, #G4470C, Agilent Technologies, Santa Clara, CA, USA). The chip consisted of 60-mer 
DNA probes and allowed simultaneous analysis of 677 rat miRNAs and 1200 human miRNAs obtained 
from the Sanger miR-BASE database (Release 16.0 for rats and 10.1 for humans). We employed approx-
imately 100 ng total RNA per sample in each experiment. RNA labeling and hybridization were per-
formed according to the manufacturer’s indications. Agilent scanner and the Feature Extraction 10.5 
software (Agilent Technologies) were used to obtain the raw-data.
Data analysis. Microarray results were analyzed by using the GeneSpring GX 13 software (Agilent 
Technologies). Data transformation was applied to set all the negative raw values at 1.0, followed by 
quantile normalization. Filters on gene expression were used to keep only those miRNAs that were 
Figure 6. Laser microdissection of the rat granule cell layer. Representative hematoxylin stained 
hippocampal section prepared from a pilocarpine treated rat (level: dentate gyrus of the hippocampus). 
(A) Intact section before laser microdissection. (B) Identification of the region of interest, the granular 
layer (black line). (C) The section after the laser microdissection, without the granular layer. Horizontal 
bar = 320 μ m.
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detected in at least one sample. Comparisons among all experimental groups (controls, early latency, 
late latency, 12 h within the first seizure and chronic) were performed with ANOVA analysis and differ-
ences were considered significant when adjusted P was < 0.1. Comparisons between two groups were 
performed with moderated t-test and considering an adjusted p < 0.1 as significant. For plasma, we 
applied ANOVA analysis and a P cutoff of 0.05. Gaussian graphical models (GGM) based on partial 
correlation were constructed using a FDR threshold of 1%. Principle components analysis (PCA) and 
boxplots were generated in R. Hierarchical clustering was performed on differentially expressed miRNAs 
with GeneSpring GX 12 software (Agilent Technologies), using the Pearson correlation as a measure of 
similarity. For cluster image generation, expression data was centered on gene median across samples.
Predicted target genes for each miRNA that was deregulated during the two earlier time point (4 and 
7 days after SE) were obtained from miRWalk using the mirDB and TargetScan algorithms57. Only those 
genes that were predicted by both algorithms were taken in consideration. The list of targets was further 
filtered using publicly available rat gene expression from the dentate gyrus (GSE49850). The predicted 
targets were filtered out if they were not present in the top two-thirds of expressed genes assayed in the 
control rats. Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) enrichment 
was performed using webgestalt (http://bioinfo.vanderbilt.edu/webgestalt/) and the terms enriched with 
adjusted p-values < 0.05 were deemed significant.
RT-qPCR. Reverse transcription (RT) reactions were performed using the Taq-Man miRNA Reverse 
Transcription kit and miRNA-specific stem-loop primers (Applied Biosystems, Inc) in a scaled down 
(7.5 μ l) reaction. Samples were run at 16 °C for 30 min, 42 °C for 30 min, 85 °C for 5 min and hold at 4 °C. 
RT products were stored undiluted at − 20 °C prior to running real-time PCR.
For GCL samples, real-time PCR reactions were performed using the TaqMan miRNA assay kit 
(Applied Biosystems, Santa Clara, CA, USA) according to the manufacturer’s instructions; for plasma, 
they were performed as described by others56. Samples were run in triplicate at 95 °C for 15 sec and 60 °C 
for 1 min using CFX96 Touch™ (Biorad, Milan, Italy). Analysis was performed by the comparative delta 
threshold cycle (Δ CT) method58. For brain samples, U6 and snoRNA were used as reference genes59. For 
plasma, data normalization was obtained using the synthetic spiked-in c. elegans miR-39.
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